Status:
UNKNOWN
Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)
Lead Sponsor:
Peking University First Hospital
Conditions:
Recurrence
Metastasis
Eligibility:
All Genders
Phase:
NA
Brief Summary
This clinical trial is designed to evaluate the role of lymph node dissection in the prevention of recurrence and metastasis after radical nephroureterectomy for high-risk primary upper tract urotheli...
Detailed Description
INTRODUCTION Upper tract urothelial carcinomas (UTUC) are relatively uncommon compared to bladder cancer and account for only 5-10% of urothelial carcinomas, with an estimated annual incidence in West...
Eligibility Criteria
Inclusion
- I. Suspected high-risk UTUC patients without metastases in their preoperative radiological imaging (cN0M0).II. Suspected high-risk UTUC patients without history of bladder tumor.
- III. Suspected high-risk UTUC patients without synchronous bladder tumor. IV. Suspected high-risk UTUC patients without contralateral UTUCs
Exclusion
- I. Patients with significant metastases in their preoperative radiological imaging.
- II. Patients with history of bladder tumor. III. Patients with synchronous bladder tumor. IV. Patients with contralateral UTUCs. V. Patients with advanced stage (T4). VI. Patients with other malignant tumors
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03230201
Start Date
January 1 2017
End Date
January 1 2021
Last Update
August 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034